高龄、合并症、糖皮质激素使用及疾病活动度是炎症性风湿与肌肉骨骼疾病患者COVID-19住院的危险因素
该研究基于德国COVID-19注册登记数据,纳入468例PCR确诊SARS-CoV-2感染的炎症性风湿与肌肉骨骼疾病(RMD)患者,评估COVID-19严重程度并识别住院危险因素。多因素分析显示,年龄>65岁(尤其>75岁)、心血管疾病、ILD/COPD、慢性肾脏病、中高疾病活动度及泼尼松等效剂量>5 mg/天的糖皮质激素治疗与住院风险升高相关;脊柱关节炎患者住院风险低于类风湿关节炎。
要点
- 年龄>75岁、心血管疾病、ILD/COPD、慢性肾脏病是COVID-19住院的强危险因素。
- 中高RMD疾病活动度及>5 mg/天糖皮质激素治疗独立增加住院风险。
- 脊柱关节炎患者住院风险低于类风湿关节炎,提示应继续充分控制RMD病情。
核心结论
- 高龄、心血管疾病、ILD/COPD、慢性肾脏病、中高RMD疾病活动度及>5 mg/天糖皮质激素治疗是RMD患者COVID-19住院的危险因素。
- 脊柱关节炎患者住院风险低于类风湿关节炎患者。
研究设计与样本
- 共纳入468例患者,采用多因素logistic回归估计COVID-19住院的OR值。
主要发现
- 29%的患者住院,5.5%需要通气,19例死亡。
- 年龄>65岁(OR 2.24;95%CI 1.12-4.47)和>75岁(OR 3.94;95%CI 1.86-8.32)与住院风险升高相关。
- 心血管疾病(OR 3.36;95%CI 1.5-7.55)、ILD/COPD(OR 2.79;95%CI 1.2-6.49)、慢性肾脏病(OR 2.96;95%CI 1.16-7.5)与住院风险升高相关。
- 中高RMD疾病活动度(OR 1.96;95%CI 1.02-3.76)及>5 mg/天糖皮质激素治疗(OR 3.67;95%CI 1.49-9.05)与住院风险升高相关。
- 脊柱关节炎住院风险低于类风湿关节炎(OR 0.46;95%CI 0.23-0.91)。
关键数值与推荐
- 年龄>65岁(OR 2.24;95%CI 1.12-4.47)和>75岁(OR 3.94;95%CI 1.86-8.32)与COVID-19住院风险升高相关。
- 心血管疾病(OR 3.36;95%CI 1.5-7.55)、ILD/COPD(OR 2.79;95%CI 1.2-6.49)、慢性肾脏病(OR 2.96;95%CI 1.16-7.5)与住院风险升高相关。
- 中高RMD疾病活动度(OR 1.96;95%CI 1.02-3.76)及>5 mg/天糖皮质激素治疗(OR 3.67;95%CI 1.49-9.05)与住院风险升高相关。
- 脊柱关节炎住院风险低于类风湿关节炎(OR 0.46;95%CI 0.23-0.91)。
临床怎么用
- 对高龄、合并心血管疾病、ILD/COPD或慢性肾脏病的RMD患者应加强COVID-19防护与监测。
- 疫情期间应继续充分控制RMD疾病活动度,避免中高疾病活动度。
- 使用>5 mg/天糖皮质激素的患者需警惕COVID-19住院风险升高。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Whether patients with inflammatory rheumatic and musculoskeletal diseases (RMD) are at higher risk to develop severe courses of COVID-19 has not been fully elucidated. Aim of this analysis was to describe patients with RMD according to their COVID-19 severity and to identify risk factors for hospitalisation. METHODS: Patients with RMD with PCR confirmed SARS-CoV-2 infection reported to the German COVID-19 registry from 30 March to 1 November 2020 were evaluated. Multivariable logistic regression was used to estimate ORs for hospitalisation due to COVID-19. RESULTS: Data from 468 patients with RMD with SARS-CoV-2 infection were reported. Most frequent diagnosis was rheumatoid arthritis, RA (48%). 29% of the patients were hospitalised, 5.5% needed ventilation. 19 patients died. Multivariable analysis showed that age >65 years (OR 2.24; 95% CI 1.12 to 4.47), but even more>75 years (OR 3.94; 95% CI 1.86 to 8.32), cardiovascular disease (CVD; OR 3.36; 95% CI 1.5 to 7.55), interstitial lung disease/chronic obstructive pulmonary disease (ILD/COPD) (OR 2.79; 95% CI 1.2 to 6.49), chronic kidney disease (OR 2.96; 95% CI 1.16 to 7.5), moderate/high RMD disease activity (OR 1.96; 95% CI 1.02 to 3.76) and treatment with glucocorticoids (GCs) in dosages >5 mg/day (OR 3.67; 95% CI 1.49 to 9.05) were associated with higher odds of hospitalisation. Spondyloarthritis patients showed a smaller risk of hospitalisation compared with RA (OR 0.46; 95% CI 0.23 to 0.91). CONCLUSION: Age was a major risk factor for hospitalisation as well as comorbidities such as CVD, ILD/COPD, chronic kidney disease and current or prior treatment with GCs. Moderate to high RMD disease activity was also an independent risk factor for hospitalisation, underlining the importance of continuing adequate RMD treatment during the pandemic.
引用
- Hasseli R, Mueller-Ladner U, Hoyer BF, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021. PMID: 33479021. doi:10.1136/rmdopen-2020-001464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。